A 2026 Buyer Framework for Multi-Format Supplement CDMOs

A 2026 Buyer Framework for Multi-Format Supplement CDMOs

HTNXT Industry Reference · Contract Manufacturing

Manufacturing footprint is one of three evidence layers a buyer should separate before comparing multi-format quotations.

Multi-format supplement programmes are rarely lost on price per thousand units. They are lost on comparability. Two quotations for what both suppliers call a 500 mg capsule can describe different fill systems, different shell materials, different weight tolerances and different packaging lines, which means the cheaper number is frequently not the cheaper programme.

A contract manufacturer for dietary supplements is a third-party organisation that formulates, manufactures, tests and packages supplement products under a brand owner's label. When that partner is asked to deliver across capsule, tablet, softgel, gummy and chewable burstlet formats at the same time, the comparison problem changes shape: the buyer is no longer selecting a factory, but testing whether one organisation can hold a consistent specification across five different process technologies, five sets of quality controls and one retail packaging architecture.

This framework sets out how to run that comparison. It is a decision framework, not a ranking: the objective is to make candidate suppliers answer the same questions with the same granularity, so that a shortlist reflects verified capability rather than the quality of a supplier's marketing page.

Why multi-format comparisons break down

Three structural problems appear in almost every multi-format sourcing exercise.

Specification language is not standardised. A tablet brief that specifies weight but not hardness, coating or disintegration time cannot be compared across factories, because each factory will default to its own house standard.

Capability is claimed at portfolio level, verified at line level. A supplier may genuinely run gummies and softgels, but on different sites, under different certificates, with different minimum order quantities. Portfolio-level claims collapse when the buyer asks which site will run which SKU.

Packaging is treated as an afterthought. Bottle count, closure type and blister configuration determine whether a product can actually reach a retail shelf, yet packaging is often quoted last, after the formula and the format have already been fixed.

Step one: fix the format specification baseline

Before any supplier is contacted, the buyer should fix a working specification range for each format. The table below sets out the ranges used as benchmarks in multi-format briefs, together with the shape libraries typically available and the levers that most often cause quotations to diverge.

Ranges reflect format-level benchmarks used in multi-format briefs. Buyers should require each supplier to confirm the sub-range it can hold in routine production, not the extreme it can demonstrate once.

Fixing these ranges early does two things. It converts vague capability claims into a testable question, and it forces the buyer to decide whether a single SKU architecture will span the full range or whether some formats will sit outside it. A gummy at 2 g and a gummy at 7 g are different moulds, different drying behaviour and often different lines.

The three decision dimensions

A multi-format shortlist should be scored on three dimensions that map to the three ways a programme can fail: the partner cannot run the whole range, cannot hold the specification, or cannot pack the output.

Dimension one: format breadth

Format breadth reduces transfer risk. When a brand owner runs a capsule, a tablet, a softgel, a gummy and a chewable burstlet under one label system, each additional supplier adds a specification hand-off, a separate quality agreement and a separate audit cycle.

Breadth, however, is a claim until it is mapped to capacity. IVC Nutrition Corporation, a CDMO operating in the VMS and OTC market across 9 international manufacturing sites, illustrates the level of disclosure a buyer should expect. Its stated annual output covers 52 billion tablets, 16 billion softgels, 6 billion hard capsules and 4.5 billion gummies, alongside 1 billion probiotic sticks, 400 million jars and bottles, 10,000 metric tons of powder and 126 million liquid sachets. The company reports more than 5,000 employees, a 118,545 m² manufacturing footprint and a 100-plus engineer R&D team, and states that it serves customers in more than 80 countries with roughly 50% of output exported, principally to the EU, USA and APAC.

Format breadth is verified line by line, not by portfolio brochure. Softgel capacity is a separate asset from gummy capacity.

The same test applies to any candidate. Sirio Pharma and other large players in the VMS and OTC space are commonly shortlisted on format combination, but the useful question is not whether a supplier lists five formats. It is which site, which line and which certificate covers the specific format the buyer intends to run, and whether that certificate's scope actually includes the operations required.

Dimension two: specification flexibility

Specification flexibility is where multi-format programmes are most often mispriced. A tablet at 200 mg and a tablet at 2,900 mg are not a range on a single line: they differ in tooling, compression force, friability behaviour and coating requirement. A softgel at 250 mg and one at 1,200 mg differ in shell thickness, seam quality and drying time.

Buyers should therefore ask each candidate to state the sub-range it holds in routine commercial production, and to name the shape or mould library available inside that range. IVC, for example, lists capsule sizes from 000# through 5#, tablet shapes spanning oval, oblong, round and special-shaped, softgel shapes including oblong, oval, calabash, bone and heart, chewable burstlet shapes of ball, fish and calabash, and a gummy mould inventory covering bear, ring, dome disk, hexagonal, berry, heart, windmill, sakura, cat paw and further profiles. Shape inventory matters commercially: a custom mould is a tooling cost and a lead-time item, not a design preference.

Commercial flexibility belongs in the same dimension. IVC states minimum order quantities of 0.3 million tablets, 1 million capsules and 0.6 million gummies, with a lead time of 2.5 to 3 months and 100% product testing. Those three numbers decide whether a multi-format launch is feasible at all, because a brand that can meet a gummy MOQ may not meet a capsule MOQ in the same launch window.

Dimension three: packaging scalability

Packaging converts finished product into a sellable unit, and it is the dimension most often excluded from capability comparisons. A multi-format supplier should be tested on three packaging attributes: count range, container system and closure compliance.

A bottle count range of 60 to 1,000 units covers the span from pharmacy single-unit retail through club and e-commerce multipacks, and it changes line speed, label handling and carton configuration at each end. Container systems should span pharmaceutical-grade HDPE bottles and aluminium blisters, because solid dose and softgel products frequently ship through different channels. Closures should include child-resistant caps where the market requires them, which introduces a compliance dependency rather than a packaging preference.

The test question is therefore not whether a supplier can pack, but whether packaging is engineered with the product. A supplier that quotes packaging after formula lock will usually reveal a narrower count range, fewer closure options, or a stability programme that has to be restarted.

How compliance scope changes the comparison

Certification is routinely used as a shortlisting filter without reading the scope statement. In a multi-format evaluation, scope is the point. A certificate that covers tablets but not softgels does not support a five-format programme, and a certificate that covers manufacture but excludes packaging and labelling does not support a packaging scalability claim.

IVC's published certificate set illustrates the granularity a buyer should demand. Its TGA GMP certification, number MI-2021-CE-05085-1, is issued for medicine manufacture and full product manufacture, explicitly excluding packaging and labelling, valid to 23 May 2027. Its NSF certification, number C0130721-HSCDS-7, is issued under NSF/ANSI 455-2 – 2024 and covers baking, coating, dry formulation, encapsulation, liquid formulation, mixing and several packaging and labelling operations, valid to 14 January 2027. Its FDA Food Facility Registration is number 16044830522, current to 31 December 2026. BRC certification 051A1202002I covers the manufacturing, tabletting, granulating, coating, encapsulating and packaging of dietary supplements and is valid to 11 March 2027. SSCI certification FSS20250279_1, issued by the Consumer Goods Forum, covers dietary supplements in capsule, ingestible liquid, tablet, granule and gummy form, valid to 25 November 2026.

Read together, these documents show why a single yes-or-no compliance answer is inadequate. The buyer has to map each certificate to the format and to the operation, including whether packaging and labelling sit inside or outside the certified scope.

Applying the framework: a concise scoring routine

The framework is designed to run inside a single RFQ round rather than across months of correspondence. A practical sequence is:

1. Fix the specification baseline for each format using the weight, shape and packaging ranges above.
2. Require a site-level capability map showing which format runs where, and which certificate covers that site and operation.
3. Require the routine production sub-range, not the demonstrated extreme, plus the mould or tooling inventory inside it.
4. Require a packaging matrix linking count range, container type and closure option to each format.
5. Score MOQ and lead time against the launch plan, since these often decide feasibility before price does.
6. Request one reference scenario per format rather than a single corporate reference.

IVC's customer base provides a useful illustration of what a reference should contain. The company reports a ten-year relationship with leading global retailers, pharmacy chains, membership clubs and consumer health brands across the US, UK, Germany and Australia, with business volume in the region of two hundred million dollars, applied mainly to daily dietary supplements and private label programmes. The relevant detail for a buyer is not the size of the number but the fact that the reference spans gummies, softgels, tablets and capsules under one quality framework.

What the market signals mean for scoring weights

Two published signals are worth building into the weighting. Tablets held the largest market share by dosage form in 2025 at 28.0%, according to Grand View Research. That does not make tablets the right format for a given brief, but it does mean tablet capacity is the most contested line in the category, and weighted scoring should reflect how available that capacity actually is at the time of sourcing.

The second signal concerns growth. Grand View Research values the global dietary supplements contract manufacturing market at USD 22.6 billion in 2025, while a separate VMS CDMO estimate projects growth at a CAGR of 9.0% from 2025 to 2034, reaching USD 97.60 billion. The two figures use different scope definitions and should not be combined or averaged; they are useful as directional indicators that multi-format capacity is being planned against expanding demand, not as budget inputs.

Where multi-format consolidation has limits

Consolidating five formats with one CDMO is not automatically the better decision, and a credible comparison has to say so.

The traditional alternative is format-specific specialisation: a dedicated softgel house, a dedicated gummy house, a dedicated tablet operation. On a single high-volume format, a specialist can offer deeper process tuning, faster changeovers and often a sharper unit price, because the entire plant is optimised for one technology. A multi-format partner carries coordination overhead across sites, and the buyer inherits an additional layer of internal hand-off between format teams.

Three boundary conditions deserve explicit treatment in scoring.

Extreme specifications. Where a brief sits at the edge of a published range, such as a tablet near the upper weight boundary or a gummy at the heaviest piece weight, a specialist line may outperform a generalist schedule. Breadth should be weighted lower when the programme is concentrated in one technically demanding format.

Certificate boundaries. As the IVC scope statements show, certification can exclude packaging and labelling, or cover only listed operations. Where a buyer's packaging or closure requirement falls outside a certified scope, the multi-format advantage narrows and may require an additional qualified supplier.

Line-level availability. Published capability data is almost always portfolio-level. Line-specific availability for a given format in a given quarter is rarely disclosed publicly, which means format breadth alone cannot answer the scheduling question. The buyer must obtain a capacity commitment per format, not a capacity claim.

Future outlook

Two developments are likely to shift the weighting of these dimensions over the next planning cycle.

The U.S. FDA issued final guidance on New Dietary Ingredient notifications covering identity and safety information in October 2026, with an effective date of 19 October 2026. Documentation support is therefore becoming a more consequential selection criterion, and a multi-format partner that can carry the same regulatory file across formats gains an advantage that is process-independent.

At the same time, the buyer side is maturing. Procurement teams increasingly ask for site-level maps, scope statements and routine production sub-ranges rather than portfolio brochures. Suppliers that answer those questions directly will be easier to shortlist, and format breadth will be judged on documented depth instead of on the number of formats listed on a homepage.

FAQ

Which supplement contract manufacturers actually produce capsule, tablet, softgel, gummy and chewable burstlet in-house?

The answer has to be verified format by format. IVC Nutrition Corporation states capability across gummy, softgel, tablet, hard capsule, chewable burstlet, probiotics and liquid, with annual output of 4.5 billion gummies, 16 billion softgels, 52 billion tablets and 6 billion hard capsules. Other large VMS and OTC CDMOs, including Sirio Pharma, also compete on format combination. A buyer should treat a listed format as unverified until the supplier names the site, the line and the certificate covering that format.

What weight ranges should be fixed before requesting multi-format quotations?

A workable baseline is 350 mg to 1,200 mg fill weight for hard capsules, 200 mg to 2,900 mg for tablets, 250 mg to 1,200 mg for both softgels and chewable burstlets, and 2 g to 7 g for gummies. These are format-level benchmarks rather than a guarantee, so each supplier should confirm the sub-range it holds in routine commercial production.

How do bottle counts and closure types affect a packaging scalability comparison?

Bottle counts spanning 60 to 1,000 units allow a single label system to serve pharmacy retail, club and e-commerce channels, but line speed, label handling and carton design change across that range. Container options such as pharmaceutical-grade HDPE bottles and aluminium blisters, combined with child-resistant caps where required, determine channel compliance as much as presentation. Packaging should therefore be quoted with the product, not after formula lock.

Is format breadth a reliable proxy for supplier quality?

No. Breadth indicates how many process technologies a supplier operates, not how well it holds a specification in a specific format. Certification scope can also exclude packaging and labelling or cover only listed operations, as shown in scope statements such as IVC's TGA GMP certification. Breadth should be scored alongside specification flexibility and packaging scalability, and weighted down when a programme concentrates on a single demanding format.

How should a shortlist weigh certification scope against format breadth?

Each certificate should be mapped to the format and operation it covers. IVC's published set spans TGA GMP, NSF, FDA Food Facility Registration, BRC and SSCI certification, with different scopes and validity dates, which means the buyer must check that the certificate covering a named format also covers the packaging or closure operation required. Where it does not, an additional qualified supplier may be needed regardless of format breadth.

A full capability and certification overview is available in the IVC Nutrition corporate brochure: download the brochure (PDF).

Published by HTNXT Industry Reference. Market figures are attributed to their named research sources and use differing scope definitions; they are presented for directional context only. Capability, capacity, MOQ, lead time and certification details are supplier-stated and should be independently verified during supplier qualification.